MetaCap

Trinity Biotech plc ADR (TRIB)

NASDAQ: TRIBHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

6.24+0.755 (+13.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TRIB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$60.00
52-week range
4.54 – 52.50
Day range
4.54 – 6.24
Volume / Avg
13.79K / 13.54K
Beta
—
Next earnings
Dec 22, 2026

52-week range

$4.54$52.50

TRIB stock today

Shares of Trinity Biotech (TRIB) finished higher on Nov 20 at $6.24, a gain of 13.76% or $0.755 per share, versus the S&P 500's 3.70% decline. Shares are 88.1% below their 52-week high of $52.50 and 37.6% above the 52-week low of $4.54, near the bottom of the past year's range. Trinity Biotech has posted a net loss over the last twelve months (EPS of -$60.00), so its P/E ratio is not meaningful.

Trinity Biotech's next earnings report is expected on Dec 22, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About Trinity Biotech

Company profile

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. John Gillard
Headquarters
Bray
Employees
287
IPO year
1992

Financial highlights

Full financials

In fiscal 2024, Trinity Biotech generated $61.6 million in revenue, up 8.3% from fiscal 2023. Trinity Biotech reported a net loss of $31.8 million, compared with a loss of $24.0 million a year earlier. Gross margin was 34.8% (up from 34.2%) and operating margin -34.4%.

Trinity Biotech annual revenue, net income and EPS
Fiscal yearFY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$61.55M$56.83M$62.52M$81.15M$101.98M
Growth+8.31%-9.10%-22.96%-20.43%+12.77%
Net income$-31.79M$-24.02M$-41.01M$875.00K$-6.39M
EPS (diluted)—————

Earnings

Earnings history
Next report
Dec 22, 2026

Trinity Biotech peers

Health Care sector
TRIB peer companies
CompanyPrice% ChgMarket capCompare
BMRABiomerica Inc.1.08-0.92%$4.97Mvs TRIB
CDIOCardio Diagnostics Holdings Inc.1.60-3.03%$4.74Mvs TRIB
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs TRIB
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs TRIB
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs TRIB
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs TRIB
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs TRIB
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs TRIB

Indexes, lists and sector

Trinity Biotech stock FAQ

What is Trinity Biotech's stock price today?

TRIB last traded at $6.24 as of Nov 20, 4:00 PM EST, up 13.76% on the day. Prices are delayed at least 15 minutes.

When is Trinity Biotech's next earnings date?

Trinity Biotech is expected to report earnings on Tuesday, December 22, 2026.

Who is Trinity Biotech's CEO?

Mr. John Gillard is the chief executive officer of Trinity Biotech plc ADR, which has about 287 employees.

What is the TRIB 52-week high?

The 52-week high for TRIB is $52.50 and the 52-week low is $4.54. The stock is currently 88.1% below its high.

Compare TRIB